The European Commission (EC) has approved Blincyto (blinatumomab) monotherapy as part of consolidation therapy for the treatment of adults with newly-diagnosed Philadelphia chromosome-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback